Skip to main content
Mankind Pharma Limited logo

Mankind Pharma Limited — Investor Relations & Filings

Ticker · MANKIND ISIN · INE634S01028 LEI · 33580067G8AZ7S8NYA02 BSE.NS Manufacturing
Open in API
Filings indexed 397 across all filing types
Latest filing 2025-04-30 Major Shareholding Noti…
Country IN India
Listing BSE.NS MANKIND

About Mankind Pharma Limited

https://www.mankindpharma.com/

Mankind Pharma Limited focuses on the development, manufacturing, and marketing of a broad spectrum of pharmaceutical formulations and consumer healthcare products. The company’s portfolio spans various therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, dermatology, and respiratory health. It maintains a significant presence in the over-the-counter segment with brands such as Manforce, Prega News, and Gas-O-Fast. The organization operates a robust research and development infrastructure dedicated to creating affordable and accessible medicinal solutions. Its operational model leverages an extensive distribution network to ensure product availability across diverse geographic regions, prioritizing high-quality healthcare delivery and patient-centric innovation.

Recent filings

Filing Released Lang Actions
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 95% confidence The document is a disclosure under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. It confirms that the Promoter and Promoter Group along with persons acting in concert have not made any encumbrance on shares during the financial year ended March 31, 2025. The document lists promoters and promoter groups with shareholdings. This type of disclosure relates to changes or confirmations in substantial shareholdings or encumbrances, which aligns with the category of Major Shareholding Notification (MRQ). The document is not a full financial report, audit, or management discussion, nor is it an announcement of voting results or a proxy statement. It is a regulatory disclosure about shareholding status under SEBI takeover regulations, fitting the MRQ category.
2025-04-30 English
Acquisition
Board/Management Information Classification · 95% confidence The document is a letter dated April 14, 2025, addressed to stock exchanges (BSE and NSE) regarding the outcome of a Board Meeting held on the same day. It details the approval of the constitution of a Structural Integration Committee, incorporation of wholly owned subsidiaries (one foreign and one Indian), and related disclosures as per SEBI Listing Regulations and circulars. The content focuses on corporate governance decisions and disclosures about subsidiaries and structural integration plans, without presenting financial statements or detailed financial performance data. The document is an announcement of board decisions and regulatory disclosures rather than a full report or financial statement. Therefore, it fits best under Board/Management Information (MANG). The document length (6359 characters) and detailed disclosures support this classification with high confidence.
2025-04-14 English
General Updates
Board/Management Information Classification · 95% confidence The document is a formal letter dated April 14, 2025, addressed to stock exchanges (BSE and NSE) regarding the outcome of a Board Meeting of Mankind Pharma Limited. The content details the approval of the constitution of a Structural Integration Committee, incorporation of wholly owned subsidiaries (one foreign and one Indian), and related disclosures as per SEBI Listing Regulations. The document includes detailed disclosures required under Regulation 30 of the Listing Regulations and SEBI circulars, which pertain to material events or information that must be disclosed to the stock exchanges. There is no financial data, earnings information, or detailed report content. Instead, it is an announcement of decisions made by the Board of Directors. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board. The document is over 6000 characters and contains substantive information about board decisions, not just a brief notice or report publication announcement. Therefore, the appropriate classification is MANG with high confidence.
2025-04-14 English
Outcome of Board Meeting
Board/Management Information Classification · 95% confidence The document is a formal letter dated April 14, 2025, addressed to stock exchanges (BSE and NSE) regarding the outcome of a Board Meeting of Mankind Pharma Limited. The content details the approval of the constitution of a Structural Integration Committee, incorporation of wholly owned subsidiaries (one foreign and one Indian), and related disclosures as per SEBI Listing Regulations. The document includes detailed disclosures under Regulation 30 of the Listing Regulations and SEBI circulars, which pertain to material events or information that must be disclosed to the stock exchanges. There are no financial statements, earnings data, or comprehensive management discussion and analysis. The document is an announcement of board decisions and corporate actions, specifically about structural integration and subsidiary incorporation, which fits the category of Board/Management Information (MANG). The length (6359 characters) and content confirm it is not a brief announcement or a report publication notice but a substantive disclosure of board decisions. Therefore, the appropriate classification is MANG with high confidence.
2025-04-14 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming no requests for dematerialization/rematerialization of shares for the quarter ended March 31, 2025. It is a compliance certificate submitted to stock exchanges and does not contain financial statements or detailed financial data. The document length is short (2049 characters) and it is primarily a regulatory compliance certificate rather than a financial report or announcement of a report. Therefore, it fits best under Regulatory Filings (RNS), which covers officer certifications and compliance documents that do not qualify as full financial reports or other specific filings.
2025-04-03 English
Amendment to AOA/MOA
Share Issue/Capital Change Classification · 95% confidence The document is a formal disclosure under SEBI Listing Regulations regarding the effective date of a Scheme of Arrangement for Amalgamation involving multiple companies merging into Mankind Pharma Limited. It details the approval by the National Company Law Tribunal (NCLT), filing of the order with the Registrar of Companies (ROC), and the consequent amalgamation and changes in authorized share capital. The document is an announcement of a corporate restructuring event and capital change, specifically the amalgamation and the resulting authorized share capital update. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. The key focus is on the capital structure change due to the merger. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length is under 5,000 characters and is a direct announcement, not a report publication or certification, so RPA or RNS are less suitable.
2025-03-29 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.